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Vitamin D deficiency is a major risk factor for cen-
tral nervous system (CNS) demyelinating diseases
including multiple sclerosis (MS) and its animal
model, that of experimental autoimmune encepha-
lomyelitis (EAE). Both vitamin D3 and 1, 25-dihy-
droxyviatmin-D3 (calcitriol) had beneficial effects
in EAE/MS. However, the exact cause of vitamin D
deficiency in EAE/MS is not clear. Previously, we
documented that lovastatin (LOV) provides protec-
tion in EAE animals via inhibition of RhoA–ROCK
signaling. Herein, we demonstrate that LOV pre-
vents the lowering of circulating 25-hydroxyvita-
min-D3 and 1,25-dihydroxyviatmin-D3 levels in-
cluding 1,25-dihydroxyviatmin-D3 levels in the
peripheral lymphoid organs and CNS of treated EAE
animals. These effects of LOV were attributed to
enhanced expression of vitamin D synthesizing en-
zyme (1-hydroxylase) in kidney and the CNS, with
corresponding reduction of vitamin D catabolizing
enzyme (24-hydorxylase) expression in the CNS of
EAE animals via inhibition of RhoA–ROCK signal-
ing. Ex vivo and in vitro studies established that
autoreactive Th1/Th17 cells had higher expression
of 24-hydroxylase than Th2/T regulatory cells, that
was reverted by LOV or ROCK inhibitor. Interest-
ingly, LOV-mediated regulation of vitamin D metab-
olism had improved vitamin D3 efficacy to confer
protection in EAE animals and that was ascribed to
the LOV- and calcitriol-induced immunomodulatory
synergy. Together, these data provide evidence that
interfering with RhoA–ROCK signaling in autoreac-tive Th1/Th17 cells can improve vitamin D3 efficacy
in clinical trials of MS and related neurodegenera-
tive disorders. (Am J Pathol 2012, 181:993–1006; http://dx.
doi.org/10.1016/j.ajpath.2012.05.028)
Multiple sclerosis (MS) is an immunologically complex
neurodegenerative disease marked by trafficking of au-
toreactive lymphocytes and mononuclear cells into the
central nervous system (CNS) with subsequent demyeli-
nation due to loss of oligodendrocytes (OLs) and axonal
degeneration.1,2 Increasing evidence suggests that
pathogenic CD4 T helper (Th) cells ie, interferon- (IFN-
)–secreting Th1 and interleukin-17 (IL-17)–secreting
Th17 cells play a central role in the inflammatory and
demyelinating pathology; whereas IL-4–secreting Th2
and regulatory T (Treg) cells keep the autoimmune re-
sponse under control.2–4 In addition, environmental fac-
tors are important in influencing MS risk.5 Therefore, un-
derstanding the molecular mechanism(s) induced by
environmental factors in immune cells involved in the
regulation of inflammatory responses will provide new
insights for the management of MS.
Strong inverse relationship between vitamin D metab-
olite concentrations and MS prevalence has been docu-
mented in conjunction with sun exposure.6 Sun exposure
is essential to induce the biosynthesis of 25-hydroxyvita-
min D3 (25-OH-D3), a substrate of CYP27B1 (1-hydroxy-
lase), which mainly occurs in the kidney, although numer-
ous cell types/tissues also express CYP27B1 to produce
1,25-dihdroxyvitamin D3 [1,25-(OH)2D3], that provides
beneficial effects in MS.7,8 Recently, a positive associa-
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tations and MS prevalence,9 supporting the notion that
higher in situ 1,25-(OH)2D3 levels are important to limit MS
pathogenesis. The transcriptional regulatory functions of
1,25-(OH)2D3 are mediated by the nuclear vitamin D re-
ceptor (VDR),10 and genetic epidemiological studies
have shown that the VDR b allele correlated well with MS
risk in Japan.11,12 1,25-(OH)2D3 is inactivated by mito-
chondrial enzyme, CYP24A1 (24-hydroxylase) in the kid-
ney, including other cell types/tissues by hydroxylation at
24 carbon position.8 Vitamin D3 and 1,25-(OH)2D3 are
documented to inhibit experimental autoimmune enceph-
alomyelitis (EAE; murine model of MS) as well as to re-
verse established EAE.13–17 Importantly, dietary intake of
vitamin D3 and higher circulating levels of 25-OH-D3 are
documented to reduce MS prevalence.18,19 In addition,
MS clinical trials conducted with higher dose of vitamin
D3 for short durations were found to be protective and
safe in patients.20–23 However, the underlying mecha-
nism(s) responsible for vitamin D deficiency in MS/EAE is
not clear.
Seasonal changes in the circulatory 25-OH-D3 levels
were inversely related to the plasma cholesterol and tri-
glycerides levels,24,25 indicating that lowering of plasma
lipids can increase the bioavailability of vitamin D metab-
olites in human patients. Consistent with these findings,
the elevated circulatory 25-OH-D3 levels were associated
with reduced serum lipid profile in heart disease patients
treated with lipid-lowering drugs, statins.26,27 Importantly,
statins as montherapy and in combination with presently
prescribed MS drugs demonstrated significant reduction
of gadolinium lesions in the MS brain.28,29 These effects
of statins were ascribed to the activation of autoreactive
Th17 cell inhibition and the induction of Th1/Th2 shift in
MS patients via lowering of isoprenoids at the cellular
level, resulting in inhibition of Rho family small GTPase,
RhoA, and its downstream target, Rho kinase (ROCK), as
evident from EAE model studies.30–32 RhoA–ROCK sig-
naling controls the variety of cellular processes including
cellular signaling, proliferation, and differentiation.33 Con-
sidering that statins can increase the circulating levels of
25-OH-D3 in heart disease patients, we proposed to in-
vestigate the impact of statin treatment on vitamin D
metabolism in EAE animals. To gain more insight into the
protective mechanism, we studied the statin-mediated
regulation of vitamin D metabolizing enzyme expressions
at the cellular level and tested whether statin could im-
prove the efficacy of vitamin D3 in MS clinical trials.
Materials and Methods
Chemicals and Reagents
Unless otherwise stated, all chemicals were purchased
from Sigma-Aldrich (St. Louis, MO). Lovastatin (LOV),
Y27643, vitamin D3, and calcitriol were purchased from
EMD Chemicals (Philadelphia, PA). Anti-CYP27B1 (rec-
ognizes 57 kDa protein band) and anti-CYP24A1 (recog-
nizes 50-kDa protein band) antibodies were purchased
from Abcam (Cambridge, MA). Anti–-actin and, anti-mouse IgG, and anti-rabbit polyclonal IgG secondary
antibodies were obtained from Vector Laboratory (Burlin-
game, CA).
Animals
Female Lewis rats weighing 250 to 300 g were purchased
from Charles River Laboratory (Wilmington, MA) and
housed in the animal care facility at the Medical Univer-
sity of South Carolina throughout the experiment and
provided with food and water ad libitum. During experi-
mentation, rats were fed commercial rat chow containing
0.33 g/day vitamin D3 and 1% calcium. For experimen-
tal studies using vitamin D3–deficient diet, rats were fed
synthetic vitamin D3–deficient diet (Charles River Labo-
ratory) 20 days before MBP priming for EAE induction,
and rats showed significant reduction of circulating levels
of 25-OH-D3 and 1,25-(OH)2D3 on day 20 (data not
shown). All animal experimentations were conducted in
accord with accepted standards of humane care, as
outlined in the ethical guidelines and approved by the
Medical University of South Carolina Animal Ethics Com-
mittee.
EAE Induction and Evaluation
Procedures used for an induction of EAE are as de-
scribed previously in our publications, with slight modifi-
cations.34,35 In brief, rats received a subcutaneous injec-
tion of 30 g of guinea pig MBP in 0.1 mL of PBS
emulsified with equal volume of CFA supplemented with
2 mg/mL of mycobacterium tuberculosis H37Ra (Difco,
Detroit, MI) in the hind limb footpads on days 0 and 7.
Immediately and again 24 hours later, rats received per-
tussis toxin (200 ng, intraperitoneally, ip) in 0.1 mL PBS.
Pertussis toxin was administered to rats according to
standardized protocol in our laboratory for induction of
EAE. Similarly, control rats received subcutaneous injec-
tion of PBS and CFA emulsion in the hind limb footpads
on days 0 and 7. Rats were examined for clinical scores
by an experimentally blinded investigator daily. Clinical
score assessed on a scale of 0 to 5, as follows: 0, no
clinical disease; 1.0, piloerection; 2.0, loss in tail tonicity;
3.0, hind-leg paralysis; 4.0, paraplegia, and 5.0, mori-
bund or dead. Several times during the study, rats were
weighed. The clinical data of rats with clinical scores
4.0 were not included for statistical analysis. At the
conclusion of the study, the rats were euthanized. A
blood sample was obtained, and perfusion was done.
The kidneys, lymph nodes, and lumbar spinal cords were
removed, snap-frozen with liquid nitrogen, and stored at
70°C before RNA, protein, or 1,25-(OH)2D3 extraction.
Alternatively, the lumbar spinal cord of each rat was cut
into four small pieces and fixed in 4% paraformaldehyde
for histopathology. The blood was centrifuged, and de-
canted plasma was frozen at 70°C before analysis.
Drug Treatments
LOV (4 mg/mL) was suspended in 0.8% ethanol/0.6 N
NaOH/PBS, and pH was adjusted to 7.4 with 1N HCl.
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farnesol (5 mg/mL) was suspended in PBS; farnesyl
transferase inhibitor–277 (0.5 mg/mL) was suspended in
PBS; geranylgeranyl transferase inhibitor–298 was sus-
pended in ethanol and diluted in PBS (0.5 mg/mL);
fasudil was dissolved in 100 l of DMSO and diluted in
PBS (1 mg/mL); and 50 g/mL of calcitriol was sus-
pended in ethanol and diluted to 1 and 2 g/mL in PBS.
Drugs were administered intraperitoneally (ip) at the
specified dose, once daily, using a 1-mL insulin syringe.
Treatment was started after the onset of EAE disease (11
to 13 days post-immunization [dpi]) and continued until
the lessening of paralytic symptoms (25 dpi). Rat devel-
oping EAE with no drug treatment received an injection
(ip) of vehicle (0.8% ethanol in PBS), once daily. Control
rats received an injection (ip) of vehicle or drug, once
daily. For vitamin D3 treatment, vitamin D3 (0.25 mg/kg)
suspended in saline was administered to rats by gavage
every day. Similarly, for combination treatments, LOV and
calcitriol were administered once daily in established
EAE rats with clinical disease scores 3.0 until the less-
ening of paralytic symptoms (25 dpi).
25-OH-D3 and 1,25-(OH)2D3 Analysis
Plasma was separated from blood and the concentra-
tions of 25-OH-D3 and 1,25-(OH)2D3 were determined in
duplicate by radioimmunoassay (RIA) developed in the
laboratory of Bruce Hollis, as documented earlier.36 Lab-
oratory personnel were blinded to the samples. The mea-
surements of 1,25-(OH)2D3 in the tissues of spinal cord
were performed by extraction methods published ear-
lier.16 Briefly, tissues were extracted with chloroform-
methanol-4% KCl in water (1:2:0.8 v/v) mixture to recover
the vitamin D metabolites. The extracts were then vac-
uum dried, suspended in ethanol, diluted in sample buf-
fer, and analyzed in duplicate for 1,25-(OH)2D3 using rat
1,25-(OH)2D3 ELISA kit (NovaTeinBio, Cambridge, MA).
A spike recovery control was performed with each 1,25-
(OH)2D3 extraction by adding 100 pg of 1,25-(OH)2D3 to
a crushed spinal cord of rat fed a vitamin D3-depleted
diet for 20 days.
Stimulation of MBP-Primed Spleen Cells and
Characterization of CD4 T Cells
The spleens of MBP-primed rats were collected after the
onset of EAE with clinical score 2.0 or from naive con-
trols and processed to make single-cell suspension fol-
lowed by the removal of RBCs with 1 pharma lyses (BD
Biosciences). Cells were washed twice and suspended
in RPMI 1640, and the concentration was adjusted to 5 
106 cells/mL. Cells were plated in six-well tissue culture
plates and incubated with 50 g/mL of MBP in the pres-
ence/absence of LOV (5 mol/L) at 37°C. After 72 h,
nonadherent cells were collected by centrifugation, and
CD4 T cells were positively selected using Dynabeads
M-450 CD4 beads (Dynal Biotech, Oslo, Norway). Sepa-
ration of CD4 T cells was monitored using flow cytom-
etry analysis, demonstrating97% purity. Total RNA waspurified from collected CD4 T cells and used for real-
time PCR analysis.
In Vitro T Helper Cell Differentiation
Naive CD4CD25 T cells were purified from the spleen
single cell suspensions using magnetic cell sorting
(Miltenyi Biotec) with 98% to 99% of purity. Purified
CD4CD25 T cells were stimulated with antibodies to
CD3 (5 g/mL) and CD28 (2 g/mL) under Th17 cell
differentiation conditions (rmIL-6, 20 ng/mL; R&D sys-
tems; rhTGF-1, 3 ng/mL; anti-IL-4, 10 g/mL; and anti–
IFN-, 10 g/mL; BD Biosciences), Th1 cell differentiation
conditions (rmIL-12, 10 ng/mL and IL-4, 10 g/mL; BD
Biosciences), Th2 cell differentiation conditions (rmIL-4,
20 ng/mL; rmIL-2, 10 ng/mL, R&D Systems; and anti-
IFN-, 10 g/mL), or Treg cell differentiation conditions
(rhTGF-1, 5 ng/mL and rmILs-2, 40 ng/mL; R&D Sys-
tems) for 48 hours. This was followed by treatment with
LOV (5 mol/L) for another 24 hours to assess the ex-
pression of CYP24A1 using quantitative real-time PCR.
Histopathology
Fixed lumbar spinal cords sections of 5 m were stained
with Luxol fast blue or H&E (Sigma-Aldrich) and exam-
ined using light microscopy (Olympus BX-60) and im-
ages were acquired with an Olympus digital camera (Op-
tronics; Goleta, CA). The region of spinal cord depicting
10 nuclei was considered as a lesion. The meninges,
and the gray and white matter of the sections were
scored in a blinded fashion based on the presence or the
absence of infiltrating cells in each of the regions of the
spinal cord. The histopathology score was recorded as
the number of lesions in the spinal cord of each group
rats that showed a readily identifiable inflammatory cell
infiltrate. Similarly, luxol fast blue–stained spinal cord
sections were analyzed for degree of demyelination and
scored. The demyelination degree was scored as grade
0, no disease; grade 1, foci of demyelination/axonal loss
that was superficial and involved 25% of the lateral
columns; grade 2, deep foci that involved 25% of the
lateral columns; and grade 3, diffuse and widespread
demyelination and axonal loss.
Real-Time PCR and Transcript Analysis
For quantitative assessments of relative mRNA levels,
total RNA was prepared using TRIzol LS reagent (Invitro-
gen, Carlsbad, CA), following the manufacturer’s instruc-
tions. RNA was reverse transcribed using an MMLV-RT
reverse transcription kit with random hexamer primers
(Bio-Rad, Hercules CA). Relative levels of transcripts of
various genes described in Table 1 were determined by
real-time PCR (iCycler IQ, Bio-Rad) using a SYBR green
PCR mix (Bio-Rad). Rat-specific primers for each gene
were designed using Primer Quest software and oligonu-
cleotides were purchased from Integrated DNA Technol-
ogies Inc. (Coralville, IA). Thermal cycling conditions
were as follows: activation of iTaq DNA polymerase at
95°C for 10 minutes, followed by 40 cycles of amplifica-
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performance of each real-time PCR run was determined
by examining the melting curve. The detection of thresh-
old was set above the mean baseline fluorescence de-
termined by the first 20 cycles. Amplification reaction in
which the fluorescence increased above the threshold
was defined as positive. Values obtained for each gene
of interest were normalized to -actin or 18S rRNA tran-
scripts as an internal control.
Western Blotting
Tissues were homogenized in ice-cold lysis buffer (50
mm Tris-HCl, pH 7.4, containing 50 mmol/L NaCl, 1
mmol/L EDTA, 0.5 mmol/L EGTA, 10% glycerol, and pro-
tease inhibitor mixture), using a soincator with three to
four pulses for 30 seconds each. Samples were centri-
fuged at 12,000  g for 10 minutes at 4°C, and protein
concentration was determined in the supernatant using
Bradford reagent (Bio-Rad). SDS–polyacrylamide gel
electrophoresis (SDS-PAGE) and immunoblotting were
performed as described previously.34 Autoradiograph of
immunoblots was generated using enhanced chemilumi-
nescence detection kits (Amersham Biosciences, Arling-
ton Heights, IL). Densitometeric analysis of autoradio-
graph was performed using ImageJ software from the
NIH (available at http://rsb.info.nih.gov/ij).
Quantification of Cytokines
Slices of the spinal cords (20 to 50 mg) of rats were
soincated in 0.5 mL of PBS and centrifuged at 12,000 
g for 10 minutes at 4°C. The protein concentration in each
sample supernatant was determined using Bradford re-
agent (Bio-Rad). To quantify the levels of various cyto-
kines, ELISA kits (eBiosciences Inc., San Diego, CA)
were used as per instructions in the product manuals.
Recombinant protein of cytokines was used as standard
to measure their concentration in test samples. Levels of
cytokines in each sample in triplicate were measured
using an ELISA reader (UV-VIS spectrophotometer), and
data were normalized with protein concentration in each
Table 1. List of Primers Used for Quantitative Real-Time PCR An
Gene name
-actin FP: 5=-AGCTGTGCTATGT
18S rRNA FP: 5=-CCAGAGCGAAAGC
CYP24A1 FP: 5=-TTAGACCCGAACG
CYP27B1 FP: 5=-GGATCAGATGTTT
IL-4 FP: 5=-GGTATCCACGGAT
IFN- FP: 5=-TTTGAGGTCAACA
IL-6 FP: 5=-CAGAAGGAGTGGC
IL-23 FP: 5=-ATCACCACTGGGA
IL-17A FP: 5=-TCTGAGCCAGCCA
FoxP3 FP: 5=-AGAGTTTCTCAAG
RORt FP: 5=-AGGCCATTCAGTA
FP, forward primer; RP, reverse primer.sample.Statistical Analysis
For multiple comparisons, one-way multiple range anal-
ysis of variance followed by Bonferroni post-test was
used and P values were determined for each experiment
of three to four separate experiments using GraphPad
Prism 3.0 software (GraphPad Software, San Diego, CA).
Two-way analysis of variance plus Bonferroni post-test
was used to compare two groups over multiple time
points. Student’s t-test was used to compare two groups
of matched samples. P values 0.05 were considered
significant.
Results
Effect of LOV Treatment on Plasma Levels of
25-OH-D3 and 1,25-(OH)2D3 in EAE Rats in
Relation to Clinical Symptoms
The experiments reported here used the acute EAE
model to investigate whether LOV-mediated signaling
mechanism(s) enhances the systemic levels of vitamin D
metabolites to influence MS risk. Earlier, we and others
documented that statin-mediated inhibition of Rho family
GTPases in immune cells participates in the attenuation
of EAE pathogenesis.31,32 Therefore, we first sought to
measure the concentrations of vitamin D metabolites in
the blood of EAE rats treated with LOV or vehicle on peak
clinical exacerbations day (16 dpi) and during the less-
ening of paralytic symptoms (25 dpi). Rats were fed a
commercially available laboratory animal diet. LOV (2
mg/kg) was administered after the onset of neurological
impairments and continued until 25 dpi (Figure 1A). As
expected, an increase in the neurological impairments in
association with histopathological changes due to the
infiltration of autoreactive immune cells in the spinal
cords of EAE rats 16 dpi were attenuated by treatment
with LOV (Table 2). As illustrated in Figure 1B, plasma
levels of 25-OH-D3 were reduced significantly in EAE rats
treated with vehicle compared with controls 16 dpi and
were abrogated by treatment with LOV. This was also the
case for 1,25-(OH)2D3 plasma level in EAE rats treated
with vehicle compared with controls, which likewise was
Primer sequence
TAGACT-3=; RP: 5=-ACCGCTCATTGCCGATAGTGATGA-3=
CCAAGA-3=; RP: 5=-TCGGCATCGTTTATGGTCGGAACT-3=
TTGAAA-3=; RP: 5=-AGCAAAGAGCCAAGTGGAGCTGTA-3=
TGCCCA-3=; RP: 5=-AGGAAGTGGGTTAAGTGATGCCCA-3=
GACAGC-3=; RP: 5=-CCGTGGTGTTCCTTGTTGCCGTAA 3=
CAGGTC-3=; RP: 5=-TTTCCGCTTCCTGAGGCTGGATT-3=
AC-3=; RP: 5=-CACTAGGTTTGCCGAGTAGA-3=
AACAGA-3=; RP: 5=-TGCGAAGGATCTTGGAACGGAGAA-3=
AAGTGT-3=; RP: 5=-TTCCAACCCAAACATAGGCAC-3=
CCAAGC-3=; RP: 5=-TGCATAGCTCCCAGCTTCTCCTTT-3=
TGGAGT-3=; RP: 5=-TGTGTGGTTGTTGGCATTGTAGGC-3=alysis
TGCCC
ATTTG
CTGGC
GCCTT
GTAAC
ACCCA
TAAGG
GACTC
AGAAG
CACTG
TGTGGabrogated by treatment with LOV (Figure 1C). With less-
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25-OH-D3 in EAE rats treated with vehicle were similar to
those in controls (Figure 1B), whereas 1,25-(OH)2D3
plasma levels were still lower; albeit not significantly so, in
EAE rats treated with vehicle as compared with controls
(Figure 1C). On the other hand, 1,25-(OH)2D3 plasma
levels were significantly elevated in EAE rats treated with
LOV 25 dpi compared with vehicle-treated EAE or control
rats (Figure 1C). Moreover, a significant change in the
plasma levels of 1,25-(OH)2D3 was also evident in con-
trols treated with LOV rather than vehicle (Figure 1C).
These data provide evidence that neurological impair-
ments in association with histopathological changes in
CNS due to the infiltration of immune cells are correlated
with reduced circulating levels of 25-OH-D3 and 1,25-
(OH)2D3 in EAE animals, and were controlled by treat-
ment with LOV.
Mitochondrial cytochrome P450 enzymes ie, CYP27B1
(1-hydroxylase) and CYP24A1 (24-hydroxylase) ex-
pressed in the proximal tubules of kidney are reported to
maintain the systemic concentrations of vitamin D metab-
olites.8 We reasoned that differences in synthesis or in-activation early in the disease process would have the
greatest impact on disease outcome. Therefore, the ex-
pressions of the CYP24A1 and CYP27B1 in the kidneys of
EAE rats treated/untreated with LOV were examined. Im-
portantly, no change in the level of CYP24A1 transcripts
was observed in the kidneys of EAE treated with LOV or
vehicle, including control rats treated with LOV or vehicle
(Figure 1D), suggesting that EAE pathogenesis has no
effect on kidney physiology. However, the level of
CYP27B1 transcripts was significantly elevated in the
kidneys of EAE rats treated with LOV rather than vehicle
(Figure 1D). This LOV-mediated increase in the levels of
CYP27B1 transcripts was also evident in the kidneys of
control rats treated with LOV rather than vehicle (Figure
1D). Consistent with RNA data, a significant increase in
the level of CYP27B1 protein was observed in the kidneys
of EAE rats treated with LOV rather than vehicle (Figure 1,
E and F). A LOV-mediated increase in the level of
CYP27B1 protein was also evident in the kidneys of con-
trol rats treated with LOV rather than vehicle (Figure 1, E
and F). The observed elevated levels of CYP27B1 protein
Figure 1. Effect of LOV on clinical exacerba-
tions, vitamin D metabolites, and expression of
its metabolizing enzymes in EAE rats. EAE was
induced in female Lewis rats with guinea pig
MBP (30 g/rat), and LOV (2 mg/kg) or vehicle
treatments were initiated as described in Mate-
rials and Methods. A: Composite mean SEM of
the clinical scores of 9 to 12 rats per group
evaluated in three separate experiments. Com-
posite mean  SEM of four to five samples per
group of the levels of 25-OH-D3 (B) and 1,25-
(OH)2D3 (C) in the plasmas of treated EAE and
control rats 16 dpi and 25 dpi. D: Composite
mean  SEM of four to five samples per group
analyzed by real-time PCR in duplicate for
CYP24A1 and CYP27B1 transcript levels in the
kidneys of treated EAE and control rats 16 dpi. E:
Representative autoradiograph of four samples
per group depicting the levels of CYP27B1,
CYP24A1, and -actin proteins in the kidneys of
treated EAE and control rats 16 dpi. F: Histogram
depicts the composite mean  SEM of four sam-
ples per group analyzed by Western blotting for
CYP24A1 and CYP27B1 proteins normalized
with -actin and then compared with respective
controls in the kidneys of treated EAE and con-
trol rats 16 dpi. Statistical significance as indi-
cated: *P  0.05; **P  0.01; ***P  0.001; NS,
not significant.in the kidneys of EAE rats compared with controls (Figure
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mechanism to maintain 1,25-(OH)2D3 homeostasis in
EAE rats. Similar to RNA data, no change in the CYP24A1
protein levels was observed in the kidneys of EAE versus
controls (Figure 1, E and F). Moreover, the observed in-
crease in the CYP24A1 protein level in the kidneys of EAE
rats treated with LOV (Figure 1, E and F) is reflective of an
induction of feedback inhibition loop wherein the 1,25-
(OH)2D3 strongly induces the CYP24A1 gene.
37 Taken to-
gether, these data provide evidence that systemic inflam-
mation does not affect kidney physiology in EAE rats,
whereas LOV tends to induce the CYP27B1 gene in the
kidneys of treated EAE animals. These data explain the
above-described findings relating to how LOV increases
the circulatory levels of 1,25-(OH)2D3 in treated EAE rats.
Effect of LOV Treatment on in Situ Levels of
1,25-(OH)2D3 in the Spinal Cords of EAE Rats
The bioavailability of 1,25-(OH)2D3 in the spinal cord is
most relevant to disease outcome as EAE pathology is
confined to the CNS.1,2 Using methods published ear-
lier,16 we determined in situ levels of 1,25-(OH)2D3 and
compared them with the expressions of CYP24A1 and
CYP27B1 in the spinal cords of EAE rats treated or not
treated with LOV. At 16 dpi, the levels of 1,25-(OH)2D3 in
the spinal cords were as follows: 23  3 fmol/g in EAE,
39  7 fmol/g in EAE plus LOV, and 37  2 fmol/g in
controls. Consistent with systemic levels of 1,25-(OH)2D3,
the spinal cord levels of 1,25-(OH)2D3 were also reduced
significantly in EAE rats treated with vehicle than LOV and
compared with controls (P  0.001 and P  0.002, re-
Table 2. Effect of Lovastatin (LOV) and Various Metabolites/
Inhibitors of Mevalonate Pathways on the Disease
Severity in Experimental Autoimmune
Encephalomyelitis (EAE) Animals
Group
Disease
severity
Mortality
(%)
Sections with
lesions (%)
Vehicle 3.5  0.5 20 49  10
LOV 2.5  1.0** 0* 22  10**
MEV 4.0  0.5* 40** 70  19**
LOV  MEV 3.2  0.5NS 20NS 48  8NS
LOV  FOH 3.5  1.0NS 30NS 51  5NS
FTI-277 3.8  0.5NS 20NS 59  11NS
GGTI-298 2.8  1.0** 0* 25  12**
Fasudil 2.5  0.5** 0* 21  6**
Vitamin D3–deficient
diet
Vehicle 4.0  1.0 30 65  5
LOV 3.2  0.5* 0** 55  7*
Vitamin D3 3.0  1.0** 0** 46  6**
LOV  vitamin D3 2.5  0*** 0** 20  2**
Disease severity shown as the composite mean  SEM (n  10 to 12)
of clinical scores evaluated in three separate experiments. Rats with a
clinical score 2 for 2 consecutive days were considered to have EAE.
Histological data are of five rats per group, in which three to four sections
per rat were examined for the presence of lesions. The region of spinal
cord depicting10 nuclei was considered as lesion. Statistical tests were
performed with Student’s t-test (disease severity and mortality) and
Mann–Whitney rank sum test (histopathological data). Statistical signifi-
cance: *P 0.05, **P 0.01, ***P 0.001 and not significant (NS) versus
EAE with vehicle.spectively). Likewise, levels of CYP24A1 transcripts weresignificantly elevated in the spinal cords of EAE rats
treated with vehicle as compared with controls, and that
was reversed by treatment with LOV (Figure 2A). Impor-
tantly, a significant increase in the level of CYP27B1
transcripts was observed in the spinal cords of EAE rats
treated with LOV rather than vehicle (Figure 2A). The
CYP27B1 transcripts level was also elevated in the spinal
cords of LOV-treated controls rather than those treated
with vehicle (Figure 2A). Consistent with RNA data, in-
creased level of CYP24A1 protein in the spinal cords of
EAE rats was attenuated by treatment with LOV (Figure 2,
B and C). In addition, CYP27B1 protein level was ele-
vated in the spinal cords of LOV-treated control rats
rather than those treated with vehicle (Figure 2, B and C).
These results confirmed our conclusions that neurologi-
cal impairments due to an infiltration of autoreactive im-
mune cells were co-related with reduced in situ levels of
Figure 2. Effect of LOV on CYP24A1 and CYP27B1 expression in the spinal
cords of EAE rats. Spinal cords were collected 16 dpi from EAE and control
rats treated with LOV or vehicle as detailed in Figure 1 legend. A: Composite
mean  SEM of four to five samples per group of the levels of CYP24A1 and
CYP27B1 transcripts analyzed by real-time PCR in the spinal cord tissues. B:
Representative autoradiograph depicting the levels of CYP24A1, CYP27B1,
and -actin proteins analyzed by Western blotting in the spinal cord tissues.
C: Histogram depicting the composite mean  SEM of four to five samples
per group of the levels of CYP24A1 and CYP27B1 proteins normalized to
-actin and compared with respective controls in the spinal cord tissues.
Statistical significance as indicated: **P  0.01; ***P  0.001; NS, not
significant.
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to its inactivation by 24-hydroxylase (CYP24A1). In con-
trast, LOV represses the CYP24A1 gene induction with
corresponding induction of CYP27B1 gene that may
eventually increase in situ levels of 1,25-(OH)2D3 in the
spinal cord of EAE animals. These findings suggest that
LOV-mediated regulation of the expression of vitamin D
metabolizing enzymes in immune cells in the CNS may
contribute to limit EAE pathogenesis via induction of the
apoptosis of immune cells, as documented in an animal
model of arthritis.38
Previous studies have documented that statin-medi-
ated attenuation of CNS inflammation in EAE rats was
ascribed to the inhibition of RhoA–ROCK signaling mech-
anism in immune cells.31,32 We next sought to confirm our
hypothesis that LOV-mediated inhibition of RhoA–ROCK
signaling participates in the maintenance of vitamin D
homeostasis in treated EAE rats. To address this, we
used various metabolites or inhibitors of the mevalonate
pathway to treat EAE rats (Figure 3A), as described pre-
viously.31 LOV-mediated attenuation of the paralytic
symptoms in association with decreased CNS inflamma-
tion in treated EAE rats was reversed by co-treatment
with L-mevalolactone (MEV) or farnesol (FOH) (Table 2).
Importantly, LOV-mediated protective effects in EAE rats
were mimicked by treatment of EAE rats with gera-
nylgeranyl transferase inhibitor (GGTI-298) or Rho kinase
Figure 3. Effect
the spinal cords
with LOV alone
enzyme inhibito
the mevalonate
Plot depicts the
in the spinal cor
depicts the level
spinal cords of
(GGTI-298), farn
composite mean
statistical signific(ROCK) inhibitor (fasudil), but not with inhibitor of farnesyltransferase (FTI-277) (Table 2). Consistent with clinical
exacerbations data, LOV-mediated decrease in the level
of CYP24A1 transcripts in the spinal cords of treated EAE
rats were abrogated by co-treatment with MEV (Figure
3B). Similar was the case for CYP27B1 gene induction, as
LOV-mediated increases in the levels of CYP27B1 tran-
scripts in the spinal cords of EAE rats were reversed by
co-treatment with MEV (Figure 3B). However, LOV-medi-
ated regulation of the induction of CYP24A1/CYP27B1
genes in the spinal cords of treated EAE rats were mim-
icked by treatment with GGTI-298 or fasudil, but not with
FTI-277 (Figure 3C). Similar to the results of LOV plus
MEV experiment, FOH co-treatment also abrogated the
LOV-mediated regulation of the induction of CYP24A1/
CYP27B1 genes in the spinal cords of EAE rats (Figure
3C). Together, these data confirmed our hypothesis that
LOV-mediated increased bioavailability of 1,25-(OH)2D3
via regulation of CYP24A1/CYP27B1 gene inductions in
the CNS of EAE animals is ascribed to the inhibition of
RhoA–ROCK signaling mechanism.
Effect of LOV on in Situ Levels of 1,25-(OH)2D3
in the Peripheral Lymphoid Organs of EAE Rats
and MBP Sensitized CD4 T Cells
The development of EAE is associated with infiltration of
–ROCK signaling on the expressions of vitamin D–metabolizing enzymes in
ats. EAE was induced in rats as detailed in the Figure 1 legend, and treatment
combination with various metabolites of mevalonate pathway or specific
were initiated as described in Materials and Methods. A: Cartoon depicting
, and metabolites or enzyme inhibitors used to treat EAE rats are bolded. B:
f CYP24A1 and CYP27B1 transcripts analyzed by real-time PCR in duplicate
E rats treated with LOV or metabolites of mevalonate pathway 16 dpi. C: Plot
24A1 and CYP27B1 transcripts analyzed by real-time PCR in duplicate in the
control rats treated with various inhibitors, ie, geranylgeranyl transferase
nsferase (FTI-277) and RhoA kinase (fasudil). Results are expressed is the
from five rats per group of three separate experiments. Differences were
indicated: **P  0.01; ***P  0.001; NS, not significant.of RhoA
of EAE r
or in
r alone
pathway
levels o
ds of EA
s of CYP
EAE and
esyl tra
 SEM
ance asautoreactive CD4 T cells to the CNS from peripheral
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The immunosuppressive and apoptotic effects of 1,25-
(OH)2D3 in immune cells are measurable by its in situ
bioavailability.14 Thus, we next examined the levels of
1,25-(OH)2D3 in the peripheral lymphoid organs of EAE
rats. Levels of 1,25-(OH)2D3 were as follows: 28  7
fmol/g in EAE, 57  8 fmol/g in EAE plus LOV, and 55 
7 fmol/g in the spleens of rats. Likewise, levels of 1,25-
(OH)2D3 were as follows; 18  3 fmol/g in EAE, 40  6
fmol/g in EAE plus LOV, and 35  4 fmol/g in controls in
the draining lymph nodes of rats. Consistent with 1,25-
(OH)2D3 plasma levels, in situ levels of 1, 25-(OH)2D3 in
the peripheral lymphoid organs were significantly re-
duced in EAE rats compared with controls, and that was
significantly rescued by treatment with LOV (P  0.002
and P  0.001, respectively). Together these results
demonstrate that LOV-mediated increase in in situ levels
of 1,25-(OH)2D3 in the peripheral lymphoid organs are
contributing to limit the generation of autoreactive CD4
T cells in EAE rats.
At least three mechanisms might explain how LOV
represses the CYP24A1 gene induction in EAE rats more
completely than treated with vehicle. LOV might directly/indirectly repress CYP24A1 gene or induces the
CYP27B1 gene expression, and/or just the skewing of
immune response from Th1-Th2 and Th17-Treg cells. To
distinguish these possibilities, we next investigated
whether MBP-sensitized CD4 T cells are responsible for
the depletion of 1,25-(OH)2D3 in the peripheral lymphoid
organs and the CNS of EAE rats. Spleen cells from MBP-
primed EAE 12 dpi and naive rats were cultured ex vivo in
the presence or absence of MBP (50 g/mL) and treated
with LOV (5.0 mol/L) or ROCK inhibitor, Y27643 (2.5
mol/L), for 72 hours, as described inMaterials and Meth-
ods. Then, purified CD4 T cells from the nonadhering
cell populations were used to analyze the induction of
CYP27B1/CYP24A1 genes with parallel analysis of the
induction of various cytokine genes. Interestingly, MBP-
sensitized CD4 T cells from EAE rats demonstrated no
increase in the levels of CYP27B1 transcripts as com-
pared with those from naive rats (Figure 4A). On the other
hand, both LOV and Y27643 treatment demonstrated
significant increase in the levels of CYP27B1 transcripts
in MBP-sensitized CD4 T cells from EAE and naive rats
compared with vehicle-treated rats (Figure 4A). MBP-
Figure 4. Effect of LOV and ROCK inhibitor on
CYP24A1 and CYP27B1 expression in MBP-
primed CD4 T cells. Spleen cells were purified
from the spleens of EAE rats by methods detailed
under Materials and Methods. Spleen cells were
stimulated with MBP (50 g/mL) in the presence
or absence of LOV (5 mol/L). After 72 hours in
culture, nonadhering cells were pelleted from
the cultures and CD4 T cells were purified
using specific columns as described in Materials
and Methods. A and B: Composite mean  SEM
for three to four samples analyzed in triplicate by
real-time PCR for measuring the levels of
CYP24A1 and CYP27B1 transcripts in MBP-sen-
sitized CD4 T cells. C–F: Composite mean 
SEM for IFN-, IL-4, IL-17, and FoxP3 transcripts
levels in similarly treated MBP-sensitized CD4
T cells. G: Composite mean  SEM of three
samples analyzed in triplicate by real-time PCR
for the measurement of CYP24A1 transcripts in
CD4 T cells treated with calcitriol in the pres-
ence/absence of LOV for 24 hours. H: Compos-
ite mean of two samples per group analyzed in
triplicate by real-time PCR to measure the levels
of CYP24A1 transcripts in LOV-treated naive
CD4 T cells differentiated under Th1, Th17,
Th2, and Treg polarizing conditions, as detailed
in Materials and Methods. Differences were sta-
tistical significance as indicated: **P  0.01 and
not significant (NS) versus CON (vehicle); ††P 
0.01 and †††P  0.001 versus EAE (vehicle); and
***P  0.001 (G).sensitized CD4 T cells from EAE rats expressed higher
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naive rats (Figure 4B). These increased levels of
CYP24A1 transcripts were significantly reduced by treat-
ment with LOV or Y27643 in MBP-sensitized CD4 T cells
from EAE rats (Figure 4B). However, no change in the
expression of CYP24A1 was observed among MBP-sen-
sitized CD4 T cells from naive rats (Figure 4B). Because
Th1 and Th17 cells can initiate and perpetuate the CNS
inflammatory response in EAE, and because their devel-
opment is under the strict influence of Th2 and Treg cells,
respectively,4 we next analyzed the expression of the
signatory molecules of these cell types. We found that the
observed CYP27B1 and CYP24A1 RNA data were corre-
lated with LOV- or Y27643-mediated skewing of Th1-Th2
and Th17-Treg phenotype responses. It was evident from
a significant decrease in the levels of IFN- (Figure 4C)
and IL-17 (Figure 4E) transcripts with corresponding in-
crease in the levels of IL-4 (Figure 4D) and FoxP3 (Figure
4F) transcripts in LOV or Y27643 treated MBP-sensitized
CD4 T cells from EAE rats rather than naive rats. Be-
cause calcitriol is important in inducing the CYP24A1
gene,37 we next found that LOV attenuated the calcitriol-
mediated induction of CYP24A1 gene in MBP-sensitized
CD4 T cells (Figure 4G). Furthermore, naive splenic
CD4 T cells that were differentiated under Th1 and Th17
polarizing conditions in vitro demonstrated the increased
levels of CYP24A1 transcripts over those differentiated
under Th2 and Treg polarization conditions (Figure 4H).
Importantly, LOV treatment repressed the CYP24A1 gene
induction in these differentiated CD4 T cells under these
polarizing conditions (Figure 4H). Together, these results
provide evidence that MBP-sensitized CD4 Th1 and
Th17 cells had higher levels of the CYP24A1 transcripts
compared with MBP-sensitized Th2 and Treg cells, which
may be contributing to the inactivation of 1,25-(OH)2D3,thereby reducing its in situ levels in the peripheral lym-
phoid organs and the CNS of EAE animals. In contrast,
interference with RhoA–ROCK signaling with LOV or
ROCK inhibitor had limited the inactivation of 1,25-
(OH)2D3 in autoreactive CD4
 T (Th1/Th17) cells.
Effect of LOV on Immunosuppressive Activity of
Vitamin D3 in EAE Rats
To distinguish whether this LOV-mediated increased in
situ levels of 1,25-(OH)2D3 contributes to the immunosup-
pressive activities of vitamin D3 in EAE rats, we fed EAE
rats a diet without vitamin D3 before MBP-priming and
treatment with LOV or vitamin D3. Earlier, mice fed a diet
without vitamin D3 are documented to show severe EAE-
related exacerbations.13 Consistently, we also observed
severe neurological impairments and inflammation in
MBP-primed rats fed a diet deficient in vitamin D3, which
were reduced moderately by treatment with LOV (Table
2). Similar was the case for MBP-primed rats treated with
vitamin D3 (Table 2). Importantly, a LOV and vitamin D3
combination demonstrated greater protection in EAE rats
than did their individual doses (Table 2). Moreover, the
mortality rate in EAE rats was also reduced by a LOV plus
vitamin D3 combination (Table 2). The skewing of Th1-
Th2 phenotype response in the CNS of EAE rats was
evident from changes in the transcripts levels of signatory
cytokines, ie, IL-4 and IFN-, in the spinal cords of EAE
rats treated with LOV or vitamin D3 (Figure 5A). This
skewing of Th1 to Th2 was further enhanced in EAE rats
receiving LOV and vitamin D3 in combination (Figure 5A).
Likewise, LOV- or vitamin D3-mediated attenuation of the
Th17 phenotypic response in EAE rats was evident from
Figure 5. Effect of LOV and vitamin D3 therapy
on EAE disease in rats fed a vitamin D3–deficient
diet. Adult rats were fed a synthetic diet formu-
lated to provide no vitamin D3 for 20 days before
priming to MBP. EAE was induced and treatment
with LOV (2 mg/kg, ip) and vitamin D3 (0.25
mg/kg, po) in combination or individually were
started after the onset of disease. Composite
mean  SEM of three to four samples per group
analyzed in triplicate by real-time PCR for IL-4
and IFN- (A), IL-17A and ROR-t (B), IL-23 and
IL-6 (C), and CD25 and FoxP3 (D) transcripts in
the spinal cords of EAE and control rats treated
with LOV or vitamin D3 16 dpi. Differences were
statistical significance as indicated: *P  0.05;
**P  0.01; ***P  0.001. NS, not significant.the reduced transcripts levels of Th17 signatory mole-
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EAE rats (Figure 5B). This attenuation of Th17 cells gen-
eration was enhanced further in EAE rats receiving LOV
and vitamin D3 in combination (Figure 5B). Differentiation
of naive T cells to Th17 cells is mediated by the secretion
of IL-1 and IL-6 from dendritic cells and that synergizes
with IL-23 to secrete IL-17 by CD4 T cells.3 We found
that the elevated levels of IL-23 and IL-6 transcripts in the
spinal cords of EAE rats were reduced by treatment with
LOV or vitamin D3 (Figure 5C). However, LOV and vitamin
D3 in combination demonstrated enhanced reduction of
these cytokines in the spinal cords of EAE rats (Figure
5C). Likewise, the generation of Treg cells was evident
from the observed changes in the transcript levels of
signatory protein, ie, CD25 and transcription factor,
FoxP3 in the spinal cords of LOV or vitamin D3 treated
EAE rats compared with those that received vehicle (Fig-
ure 5D). Combination treatment with LOV and vitamin D3
had enhanced expression of these mediators in the spi-
nal cords of EAE rats (Figure 5D). Together, these data
provide evidence that LOV-mediated regulation of vita-
Figure 6. Effect of LOV and calcitriol combination on clinical exacerbation
in EAE rats. EAE was induced in adult Lewis female rats as described in Figure
1 legend. Treatment with LOV (1 mg/kg) and calcitriol (1 g/kg) was
initiated individually or in combination in established EAE rats (14 dpi) and
continued until the lessening of paralytic symptoms (25 dpi). A: Cartoon
depicting the treatment strategy of EAE rats with LOV or calcitriol. B: Com-
posite mean  SEM of clinical scores of 10 to 12 rats per group evaluated in
four separate experiments. LOV and calcitriol combination demonstrated
significant lessening of paralytic symptoms 21 to 23 dpi and completely 25
dpi compared with their individual treatments or vehicle. Statistical signifi-
cance as indicated: ***P  0.001 versus EAE (vehicle).
Table 3. Effect of Lovastatin (LOV) and Calcitriol Combination o
(EAE) Rats
Group LOV (mg/kg/wt)
Calcitriol
(g/kg/wt)
Control 0 0
Control 1 1
EAE 0 0
EAE 1 0
EAE 0 1
EAE 1 1
Disease severity shown as the composite mean  SEM (n  10 to 12
are of five rats per group, in which three to four sections per rat were exam
was considered as lesion. Demyelination was categorized as score of 0
superficial and involves 25% of the lateral columns; grade 2 denotes d
and widespread demyelination/axonal loss. Statistical tests were performed wi
(histopathological data). Statistical significance: *P  0.05, **P  0.01, and ***Pmin D metabolism has an additive effect to improve the
efficacy of vitamin D3 in EAE animals.
Effect of LOV and Calcitriol Combination on
CNS Inflammation and EAE Development
To further confirm that LOV-mediated increased efficacy
of vitamin D3 in EAE animals is ascribable to the in-
creased bioavailability of 1,25-(OH)2D3, we performed
the preclinical testing of LOV and 1,25-(OH)2D3 (cal-
citriol) using their suboptimal doses in combination or
alone. We performed our experimentation in rats with
established EAE as in clinical settings of MS, therapeutic
intervention is often started after the onset of the symp-
toms (Figure 6A). Administration of LOV and calcitriol in
combination during established EAE significantly ame-
liorated neurological impairments as compared with
those in vehicle-treated EAE rats and were better than
the effects of their individual treatments (Figure 6B
and Table 3). In addition, LOV and calcitriol combina-
tion treatment decreased the number of inflammatory
lesions in the spinal cords of EAE rats compared with
those treated with vehicle, which was better than the
effects observed with their respective treatments (Ta-
ble 3). Likewise, LOV and calcitriol in combination re-
duced the degree of demyelination in the spinal cords
of EAE rats compared with those treated with vehicle,
which was, again, greater than the effects seen with
their respective treatments (Table 3).
To validate the observed improvements in neurological
impairments, inflammation, and demyelination in EAE
rats, we next evaluated the influence of LOV and calcitriol
combination on T cell–mediated immunity in treated EAE
rats. Administration of LOV plus calcitriol combination
attenuated Th17 phenotype responses, as evident from
the reduced levels of the IL-1, TNF-, IL-17A, and IL-6
proteins in the spinal cords of EAE rats compared with
those treated with vehicle only (Table 4). In addition, the
administration of LOV plus calcitriol had favored the gen-
eration of Treg cells as evident from the increased levels
of the TGF-1 and IL-10 proteins in the spinal cords of
EAE rats as compared with those treated with vehicle
only (Table 4). Importantly, LOV plus calcitriol combina-
ase Severity in Experimental Autoimmune Encephalomyelitis
ase recovery,
25 dpi
Degree of
demyelination
Sections with
lesions (%)
0 0 0
0 0 0
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clinical cores evaluated in three separate experiments. Histological data
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AJP September 2012, Vol. 181, No. 3tion effects in EAE rats were greater than the effects
observed with their respective treatments (Table 4). To-
gether, these data provide evidence that LOV-mediated
regulation of vitamin D metabolism improves vitamin D3
efficacy to confer protection in EAE animals ascribable to
the immunomodulatory synergy between LOV and 1,25-
(OH)2D3 (calcitriol).
Discussion
Vitamin D deficiency is a risk factor for MS patients, as
dietary intake of vitamin D3 or higher circulatory 1,25-
(OH)2D3 levels are reported to reduce MS preva-
lence.18,19 Our findings provide unprecedented evi-
dence that autoreactive Th1/Th17 CD4 cells are
responsible for vitamin D deficiency in EAE animals,
which can be rescued by interfering with the RhoA–
ROCK signaling pathway.
Importantly, the reduced circulating levels of 25-
OH-D3 and 1,25-(OH)2D3 during the peak clinical day,
but without significant change on recovery phase in EAE
animals compared with controls (Figure 1, A–C), were
consistent with previous published studies in EAE and
MS.18,39 This alteration of 25-OH-D3 and 1,25-(OH)2D3
levels in EAE animals were rescued by treatment with
LOV (Figure 1, A–C). Likewise, the reduced in situ levels
of 1,25-(OH)2D3 and increased CYP24A1 (24-hydroxy-
lase) expressions in the peripheral lymph nodes and
spinal cords of EAE animals were consistent with previ-
ous study16 and were reversed by LOV with a corre-
sponding increase in CYP27B1 (1-hydroxylase) expres-
sions in treated EAE animals (Figure 2, A–C). Importantly,
EAE disease had no effect on the CYP24A1/CYP27B1
expressions in the kidneys of EAE animals. On the con-
trary, LOV enhanced CYP27B1 expression in the kidneys
of treated EAE and control animals (Figure 1, D–F). This
LOV-mediated regulation of CYP24A1/CYP27B1 expres-
sion in the CNS of EAE animals (Figure 3, B and C) and
in MBP-sensitized CD4 Th1/Th17 cells in ex vivo and in
vitro studies (Figure 4) was ascribed to the inhibition of
the RhoA–ROCK signaling pathway. We next found that
LOV-mediated regulation of the expression of vitamin D
metabolizing enzymes had improved vitamin D3 efficacy
to confer protection in EAE animals (Table 2 and Figure
5), which was ascribed to immunomodulatory synergy
between LOV- and calcitriol-induced protective activities
Table 4. Effect of Lovastatin (LOV) and Calcitriol Combination o
Encephalomyelitis (EAE) Rats
Groups CON
CON  LOV 
calcitriol EAE
IL-1 150  41 122  35 625 
TNF- 6  2.2 9.6  2 38 
IL-17A 30  4.5 29  7.5 226 
IL-6 15  0.9 22  6 129 
TGF-1 10  2 13 2.3 25 
IL-10 7  0.2 9  2.1 15 
Concentration of cytokines and neurotrophic factors (pg/mg of spina
evaluated in three separate experiments. Statistical tests were perform
post-test correction. Statistical significance: **P  0.01 and ***P  0.001(Tables 3 and 4 and Figure 6).Protective effects of 1,25-(OH)2D3 are attributed to its
interaction with receptor, VDR, that inhibits the prolifera-
tion and differentiation of myelin-reactive CD4 T cells in
EAE40 as well as regulates the expressions of CYP24A1/
CYP27B1 in cells.37 The observed reduced in situ levels
of 1,25-(OH)2D3 in the peripheral lymphoid organs and
the spinal cords of EAE animals were associated with
increased number of autoreactive immune cells (Th1/
Th17) revealed by their higher signatory transcript levels
(Figure 2), expressing higher levels of CYP24A1 that lead
to the inactivation of 1,25-(OH)2D3. This was in agree-
ment with a previously documented sexual disparity for
vitamin D metabolism in EAE and MS that shows positive
correlation with increased expression of CYP24A1 in au-
toreactive CD4 T cells and inactivation of 1,25-(OH)2D3
in males over that in females.16,39 Interestingly, LOV-
mediated inhibition of CYP24A1 gene expression in Th1/
Th17 cells may be allowing 1,25-(OH)2D3 to accumulate
in the peripheral lymphoid organs and spinal cords. The
exact mechanism by which LOV regulates the expres-
sions of CYP24A1/CYP27B1 in immune cells warrants
further investigation. Importantly, our data showed that
LOV-mediated regulation of the expression of CYP24A1
and CYP27B1 genes was ascribed to the inhibition of
RhoA–ROCK signaling pathway in the spinal cords of
EAE animals (Figure 3, B and C) as well as in MBP-
sensitized CD4 T (Th1/Th17) cells (Figure 4, A and B).
Importantly, the induction of CYP24A1 and CYP27B1
genes is tightly regulated by 1,25-(OH)2D3-/VDR induced
transcriptional activities in cells.37 The dimerization of
VDR with retinoid X receptor (RXR) promotes its nuclear
localization and subnuclear targeting to the promoter of
target gene.41,42 Peroxisome proliferator–activated re-
ceptor– (PPAR-) is known to heterodimerize with RXR
as VDR to induce the targeted gene expression in cells.43
We and others reported earlier that statin induces the
transcriptional activity of PPAR- in cells via inhibition of
RhoA–ROCK signaling pathway.44,45 Based on this infor-
mation, we postulate that statin-induced PPAR- tran-
scriptional activity may be participating in the regulation
of the expression of vitamin D metabolizing enzyme in
treated EAE animals. We reasoned that PPAR- activa-
tion may compete with VDR for common RXR ligand, ie,
9-cis retinoic acid, which, in turn, represses CYP24A1
gene induction, but switches on CYP27B1 gene induction
in cells, as activated VDR is known to repress CYP27B1
kines in the Spinal Cords of Experimental Autoimmune
EAE  LOV EAE  calcitriol
EAE  LOV 
calcitriol
389  38** 344  75** 169  39***
19.3  1.8** 15.1  3.9** 10.8  0.2***
93  0.2** 116  22.3** 28  9***
46.2  3** 61  5** 29  3***
71  11** 79  7** 161  12***
45  8** 53  5.7** 123  21.4***
tissue homogenate) shown as composite mean  SEM (n  10 to 12)
g one-way multiple-range analysis of variance followed by Benferrroni
EAE plus vehicle.n Cyto
26
4
15
8
3.6
2.8
l cordgene induction in cells.37 The present findings provide
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RhoA–ROCK signaling pathway in immune cells in-
creases 1,25-(OH)2D3, levels both locally and systemi-
cally. Therefore, a greater understanding of possible
cross-talk between PPAR- and VDR in immune cells will
suggest new therapeutic interventions for MS manage-
ment. The availability of conditional knockout mice for
cell-specific deletion of RhoA and ROCK will expand our
understanding of molecular mechanisms that participate
in the maintenance of vitamin D homeostasis.
Both 1,25-(OH)2D3 and statin are documented to atten-
uate EAE disease development via inhibition of Th17 phe-
notype response with generation of Treg cells and induction
of immunomodulatory Th1 to Th2 shift.13–16,35,40,46 In addi-
tion, higher concentrations of 1,25-(OH)2D3 are reported to
sensitize the inflammatory cells to apoptotic signals.17,38
A recent study documented that calcitriol-mediated im-
munomodulatory activities are linked with induction of
VDR transcriptional activity in Th1/Th17 cells in EAE an-
imals.15 This signifies the importance of observed skew-
ing of Th1–Th2 and Th17–Treg responses in EAE animals
treated with LOV in combination with vitamin D3 or cal-
citriol (Figures 5 and 6 and Tables 2–4), attributed to their
immunomodulatory synergy to confer protection in EAE
animals. It is noteworthy that both LOV and 1,25-(OH)2D3
can cross the blood–brain barrier because of their lipo-
philic nature.47,48 Therefore, the observed protective ef-
fects of LOV and 1,25-(OH)2D3 in the CNS of EAE animals
are not restricted to immune cells but are found in part in
brain cells also, as they are known to express VDR and
CYP27B1.49,50 In addition, statins are known to attenuate
the activation of brain cells in vitro and in vivo.31,34,51–53
Therefore, further studies are warranted with transgenic/
knockout models with cell-type expression of vitamin D
metabolizing enzymes to distinguish between the direct
effect of these agents on inflammatory immune cells and
brain cells that confer protection in EAE model.
Findings from the present study are novel that provide
a rationale to test statin or other inhibitors of RhoA–ROCK
signaling ie, fasudil or chemical inhibitor of CYP24A1
(presently under investigation in cancer54,55) in combina-
tion with reduced dose of vitamin D3 to minimize the
potential side effects of its higher dose when prescribed
for longer duration in patients with MS. Clinical trials con-
ducted so far with vitamin D3 in small numbers of MS
patients have shown efficacy.20,21 Importantly, 1, 25-
(OH)2D3 analog in combination with interferon 1 (IFNB-
1b) showed superior protection in EAE animals as com-
pared with their respective treatments.23 These findings
provide an opportunity to improve current treatment strat-
egies for MS, through combination therapy with an agent
that can increase the bioavailability of 1,25-(OH)2D3. Use
of statins for MS is still controversial, as results from statin
trials are mixed.29,56,57 One study reported that the com-
bination of a statin with IFNB was antagonistic,56 whereas
other small studies suggested that there could be bene-
fit.28,29 Likewise, of two recent reports, one showed the
adverse effect of statin in combination with IFNB in a
phase II clinical trial in MS patients, and the second
showed no beneficial effects.58,59 More recently, a mul-
ticenter randomized clinical trial with atorvastatin asadd-on therapy to IFNB-1b in younger MS patients
showed no beneficial effects.60 One possibility of this
failure of statin as add-on therapy in combination with
IFNB trials could be their antagonizing mechanism of
actions in MS.60,61 However, this does not rule out the
possibility of testing statin in combination with other MS
therapeutics (glatiramer acetate) or disease-modifying
agents that demonstrate protection in EAE.62–65 Impor-
tantly, the present study suggests that a combination of
statin with disease-modifying agent, ie, vitamin D3 as
add-on therapy with Food and Drug Administration–ap-
proved MS drugs will make them useful for the manage-
ment of MS.
In summary, the present study demonstrates that re-
duced circulating levels of 25-OH-D3 and 1,25-(OH)2D3
and in situ levels of 1,25-(OH)2D3 in the peripheral lym-
phoid organs and CNS of EAE animals can be rescued
by interfering with the RhoA–ROCK signaling pathway in
autoreactive immune cells. Findings from this study pro-
vide evidence that targeting of the RhoA–ROCK signaling
pathway in autoreactive CD4 T cells with statin or other
chemical inhibitors as add-on therapy to MS therapeutics
will reduce the dose of vitamin D3 in clinical trials of MS
and related neurodegenerative disorders, including dia-
betic neuropathy.
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